As shown in Table II, there were no statistically significant differences in maternal data between metformin and insulin groups in this study except for postprandial plasma glucose
and treatment satisfaction.
Abbreviations HbA1: Glycated haemoglobin FPG: Fasting plasma glucose PPG: Postprandial plasma glucose
CV: Cardiovascular OGTT: Oral glucose tolerance test CGM: Continuous glucose monitoring MAGE: Mean amplitude of glucose excursions SD: Coefficient of variation ADAG: A1c-Derived Average Glucose eAG: Estimated average glucose aPPG: Apparent postprandial glucose SE: Standard error.
Mean two hours postprandial plasma glucose
in group A was 7.
Contributions of fasting and postprandial plasma glucose
increments to the overall diurnal hypoglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).
They reduced fasting and postprandial plasma glucose
levels as well as the 10-hour glucose area under the curve to the same extent as that of immediate-release metformin, without changing the insulin area under the curve.
Consumption of both resistant starch and beta-glucan improves postprandial plasma glucose
and insulin in women.
Control of postprandial plasma glucose
level is critical in the early treatment of DM and in reducing chronic vascular complications (Ortiz-Andrade et al.
Wolever et al (ll7), investigated effect of low glycaemic load on postprandial plasma glucose
and insulin in 34 subjects with impaired glucose tolerance and showed that reducing the fasting glycaemic load of the diet for 4 months significantly reduces postprandial plasma glucose
concentration and plasma insulin.
5% - 11% indicated that once-daily morning dosing of CYCLOSET provided significant postprandial plasma glucose
reductions throughout the day without increasing plasma insulin concentrations and significantly improved HbA1c.
After 12 weeks of therapy, fasting, postprandial plasma glucose
, and HbA1c levels were reduced in all the three groups significantly, but the reduction in these parameters was more pronounced in the group receiving higher dosage of bromocriptine.
Fasting and postprandial plasma glucose
were estimated by Glucose oxidase-Peroxidase method.
The new tablet combines the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, the active ingredient in Tradjenta tablets which are already marketed in the US, and metformin, a commonly used antihyperglycemic drug that improves glucose tolerance by lowering both basal and postprandial plasma glucose
Relation of fasting and postprandial plasma glucose
to glycosylated hemoglobin in diabetic patients.
Postprandial hyperglycaemia: Recent studies indicate that elevated postprandial plasma glucose
levels are an independent and clinically significant risk for cardiovascular disease in non-diabetic and diabetic individuals and is associated with a two-fold increase in cardiovascular risk.